Genentech invests in DualityBio's antibody-drug conjugate platform to counter TOPO1 inhibitor resistance
DualityBio has entered a collaboration with Roche's Genentech, receiving $45 million upfront to develop antibody-drug conjugates designed to address resistance to TOPO1 inhibitors. The deal could yield over $1 billion in milestone payments. This partnership aims to advance a new generation of ADC therapies.
Expanded Detail
EXPANDED:
The collaboration centers on antibody-drug conjugates, a therapeutic class that links tumor-targeting antibodies to cell
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Roche pays $190M upfront for Hanmi's muscle-sparing obesity drug · Drug development
GSK secures global rights to Hutchmed's dual-target cancer therapy in $110M upfront deal · Cancer research
Biohaven partners with SK Biopharmaceuticals on epilepsy drug in $795M deal · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance.” Browse more stories.